A novel siRNA–gemcitabine construct as a potential therapeutic for treatment of pancreatic cancer

The non-nucleoside analog gemcitabine has been the standard of care for treating pancreatic cancer. The drug shows good potency in pancreatic cancer cells in vitro but, due to poor bioavailability, requires administration in large doses by infusion and this systemic exposure results in significant t...

Descripción completa

Detalles Bibliográficos
Autores principales: Simonenko, Vera, Lu, Xiaoyong, Roesch, Eric, Mutisya, Daniel, Shao, Chunbo, Sun, Qian, Patterson-Orazem, Athéna, McNair, Marcus, Shanmuganathan, Aranganathan, Lu, Patrick, Evans, David M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Nucleic Acid-Based Cancer Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8209983/
https://www.ncbi.nlm.nih.gov/pubmed/34316688
http://dx.doi.org/10.1093/narcan/zcaa016

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8209983/
https://www.ncbi.nlm.nih.gov/pubmed/34316688
http://dx.doi.org/10.1093/narcan/zcaa016

Ejemplares similares